

# Erratum: Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study

Doug W Gould,<sup>1</sup> James Doidge,<sup>1</sup> M Zia Sadique,<sup>2</sup>  
Mark Borthwick,<sup>3</sup> Robert Hatch,<sup>4</sup> Fergus J Caskey,<sup>5,6</sup>  
Lui Forni,<sup>7,8</sup> Robert F Lawrence,<sup>9</sup> Clare MacEwen,<sup>3</sup>  
Marlies Ostermann,<sup>10</sup> Paul R Mouncey,<sup>1</sup>  
David A Harrison,<sup>1</sup> Kathryn M Rowan,<sup>1</sup>  
J Duncan Young<sup>4</sup> and Peter J Watkinson<sup>4\*</sup>

<sup>1</sup>Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC), London, UK

<sup>2</sup>Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK

<sup>3</sup>John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>4</sup>Kadoorie Centre for Critical Care Research and Education, NIHR Biomedical Research Centre, Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>5</sup>UK Renal Registry, Bristol, UK

<sup>6</sup>Population Health Sciences, University of Bristol, Bristol, UK

<sup>7</sup>Department of Clinical and Experimental Medicine, Faculty of Health Sciences, University of Surrey, Guildford, UK

<sup>8</sup>Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK

<sup>9</sup>Patient representative, Oxford, UK

<sup>10</sup>Department of Intensive Care, Guy's and St Thomas' NHS Foundation Trust, London, UK

\*Corresponding author

Erratum issued April 2022

Erratum DOI: 10.3310/ZXH19396-c202204

Original DOI: 10.3310/ZXH19396

This report should be referenced as follows:

Gould DW, Doidge J, Sadique MZ, Borthwick M, Hatch R, Caskey FJ, *et al.* Erratum: Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study. *Health Technol Assess* 2022;**26**(13). Erratum in *Health Technol Assess* 2022;**26**(13):58–59.

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

## Erratum notice

### Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study

Doug W Gould, James Doidge, M Zia Sadique, Mark Borthwick, Robert Hatch, Fergus J Caskey, Lui Forni, Robert F Lawrence, Clare MacEwen, Marlies Ostermann, Paul R Mouncey, David A Harrison, Kathryn M Rowan, J Duncan Young and Peter J Watkinson

This paper<sup>1</sup> is corrected as follows:

Data changes have been made in *Abstract*, *Scientific summary*, *Chapter 4*, section *Calendar days of organ support*, *Table 6*, and *Chapter 5*, section *Primary economic outcome: cost-effectiveness at 1 year*.

*Figures 5–9* and *12–15* have been revised.

#### Reference

1. Gould DW, Doidge J, Sadique MZ, Borthwick M, Hatch R, Caskey FJ, *et al*. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study. *Health Technol Assess* 2022;**26**(13).